Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 0.87 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.56 |
| ▸ | HNF4A | P41235 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12915326 | 0.93 | KIF11 (1.00) | KIF11GAANLRP3HNF4A | |
| SCHEMBL12915322 | 0.93 | KIF11 (1.00) | KIF11GAANLRP3HNF4A | |
| SCHEMBL12916153 | 0.85 | KIF11 (0.88) | KIF11GAANLRP3HNF4A | |
| SCHEMBL12915482 | 0.85 | GAA (0.66) | KIF11GAASIGMAR1 | |
| SCHEMBL12751147 | 0.84 | KIF11 (0.69) | KIF11GAANLRP3HNF4ASIGMAR1 | |
| SCHEMBL12751149 | 0.84 | KIF11 (0.69) | KIF11GAANLRP3HNF4ASIGMAR1 | |
| SCHEMBL12915580 | 0.84 | KIF11 (1.00) | KIF11NLRP3HNF4ASIGMAR1 | |
| SCHEMBL28162395 | 0.84 | KIF11 (0.86) | KIF11GAANLRP3HNF4A | |
| SCHEMBL12915472 | 0.82 | KIF11 (0.88) | KIF11NLRP3HNF4ASIGMAR1 | |
| SCHEMBL15321114 | 0.82 | KIF11 (0.79) | KIF11GAANLRP3HNF4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | MERCK PATENT GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | MERCK PATENT GMBH (DE) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200451-A1 | Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 | KIF5A, KIF5C, KIF5B | KIF11 22/4885GAA 2068/4885NLRP3 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.